| INTRODUC TI ON
Cancers are a leading cause of death worldwide, and screening is an important part of clinical practice to reduce morbidity and mortality through early detection. Many benign and malignant tumours are known to be sex hormone-dependent; however, it is unclear whether the risk of these neoplasms is different amongst transgender individuals undergoing gender-affirming hormone therapy (GAHT). 1, 2 This is important to investigate, given that such hormone therapy is typically started at a young age and often continues lifelong. 3 Uptake of screening is also a major barrier and, given a limited evidence base in transgender individuals as well as frequent dysphoria to secondary sexual characteristics, complacency to undertake cancer screening may arise. with significantly improved quality of life, reduced anxiety and depression and lower suicidality. 6 There is a lack of formal epidemiological data on the prevalence or incidence of transgenderism across any age group; however, estimates are that between 0.5% and 1.3%
of the population identify as transgender and the demand for transgender health services is rising.
7
Many cancers, such as breast or prostate, are sex hormonedependent. Other typically benign, but potentially malignant tumours, in particular meningiomas and prolactinomas, display a significant difference in gender-specific prevalence, raising the question as to the role of sex hormones in their pathogenesis. 8 As many as 31 different organ-specific malignancies have been found to express sex hormone receptors. 9 However, there is little data available on the effect of GAHT on the development of hormone-dependent neoplasms amongst transgender individuals.
Whilst there is insufficient evidence, international guidelines published by the World Professional Association for Transgender
Health in 2012 and the Endocrine Society in 2017 suggest oestrogens pose a moderate risk of developing prolactinoma and breast cancer, with testosterone therapy associated with a moderate risk of breast and endometrial cancer. 4, 5 Given the paucity of evidence, current cancer and tumour-screening guidelines for transgender individuals on GAHT are based on the recommendations for individuals of the corresponding birth-assigned gender. 4 Evidence also suggests that a lack of knowledge, and potentially discrimination from the part of the medical profession, can result in suboptimal cancer screening for transgender individuals. 
| ME THODS
Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) reporting guidelines were used in the development of this systematic review. 
| Eligibility criteria
All levels of evidence were included in this review and provided that the report was published in a peer-reviewed journal and in the English language.
No randomized controlled trials or prospective observational studies were identified. All included studies were observational retrospective cohort studies and one-time cross-sectional studies, as well as case reports and case series.
Observational studies (ie, cohort and cross-sectional studies) were eligible for this review if enrolled participants were transgender and had commenced GAHT. Participants must have already been diag- Participants must have commenced GAHT, consisting of a minimum of exogenous oestrogen (for male-to-female transgender individuals) or testosterone (for female-to-male transgender individuals) therapy. All forms of testosterone-or oestrogen-containing GAHT were accepted, regardless of route of administration, dosage, dosing frequency or the presence of additional exogenous hormones (eg, anti-androgens, progestins). Furthermore, only studies in which the diagnosis of a neoplasm was made subsequent to GAHT commencement were included.
Both benign and malignant neoplasms were included.
Case studies were eligible: if hormone therapy definitively preceded tumour diagnosis; if the duration and type of hormone therapy was stated; and if the age at the time of diagnosis was known.
There were several isolated case reports describing tumour development in an individual receiving GAHT; however, the significance of this was unclear. Therefore, we required two or more case reports per histological tumour type for these to be included in the review.
| Information sources and search strategy
The first author consulted an expert reference librarian to design and conduct the electronic database search with input from the last author.
Eligible studies were identified by searching the following electronic databases from inception to 1st gender" (all terms) OR "transsexualism" (all terms) OR "sex change" (all terms) OR "gender identity" (all terms) OR "gender identity disorder" (all terms)) AND (("sex hormones" (all terms) OR "estrogens" (all terms) OR "estradiol" (all terms) OR "cross-sex hormone therapy" (keyword) OR "hormone therapy" (all terms) OR "testosterone" (all terms) OR "estrogens" (all terms) OR "estradiol" (all terms) OR "antiandrogens" (all terms)
OR "androgens" (all terms)) AND "neoplasms" (all terms).
Finally, our search of the Embase® database consisted of the following Emtree terms and keywords: ("transgender" (all terms) OR "transsexual" (keyword) OR "gender dysphoria" (all terms) OR "gender identity" (all terms) OR "sex transformation" (all terms)) AND ("cross-sex hormone therapy.m.p." OR "hormonal therapy" (all terms)
OR "testosterone" (all terms) OR "estrogen" (all terms) OR "estradiol"
OR "antiandrogen" (all terms) OR "cyproterone acetate" (all terms)
OR "cyproterone" (all terms) OR "spironolactone"(all terms)) AND "neoplasms" (all terms).
Bibliographies of identified studies were also consulted to identify further articles.
| Study selection
Our full search strategy is outlined in Figure 1 .
| Data collection
Data were collected via an electronic form to capture the data items listed below.
| Data items

| Participant characteristics
Age, birth-assigned sex, gender identity, GAHT duration. (as opposed to mean age).
| Study characteristics
Study design, recruitment method, inclusion/exclusion criteria, location, sample size.
| Control or comparison population
Recruitment method, setting, age, birth-assigned sex.
| Outcomes
Description of context in which tumour was diagnosed, histological type, immunohistochemistry features of tumour such as sex hormone receptor staining, other pertinent neoplasm-specific serum investigations.
| Statistical results
Adjusted and unadjusted prevalence or incidence estimates and measures of variability, number of patients.
| Summary measures
For cohort studies, statistically significant (P < 0.05) differences in neoplasm incidence or mortality between transgender and comparison samples were analysed. The summary measures were incidence rate, standardized incidence ratio or standardized mortality ratio.
For cross-sectional studies, statistically significant (P < 0.05) differences in neoplasm prevalence between transgender and comparison samples were analysed.
| Synthesis of results
Data were collated and outcome variables were grouped as follows:
standardized incidence ratio, incidence, standardized mortality ratio, prevalence.
| RE SULTS
A total of 268 studies were identified using MEDLINE, Embase and PsycINFO and 39 additional studies were identified from bibliographic references. After screening title and abstracts, 76 duplicate results were removed, 161 were removed due to lack of relevance, 10 for being in a language other than English and 3 for not being published in a peerreviewed journal. A further 2 cohort studies and 7 case studies were excluded as no data were available regarding the temporal duration of the hormone therapy, age at diagnosis and details regarding whether the cancer predated the commencement of hormone therapy. Of the 48 remaining studies, there were 7 retrospective cohort studies, 2 crosssectional studies (Table 1 ) and 39 case reports (Tables 2 and 3 ).
TA B L E 2
Case reports in which a female-to-male transgender individual was diagnosed with a primary tumour following commencement of GAHT TA B L E 3 (Continued) 
| Retrospective Cohort Studies
| Cross-sectional studies
Two cross-sectional studies have been published based on data from a well-established gender clinic in Belgium 18, 19 (Table 1 ).
The initial report of 100 transgender individuals found no cancer diagnoses after mean of 10 years of hormone therapy.
19
However, when additional individuals were assessed (138 female-to-male mean duration 6.0 years on hormone therapy and 214 male-to-female individuals mean duration 7.0 years on hormone therapy), several cancers were identified only in the male-to-female group which was not significantly different to the male general population. No cancers were identified in the female-to-male group. 
| Case reports
A large number of case reports were identified which reported tumour development following the commencement of GAHT. Case reports in female-to-male individuals are summarized in 
| D ISCUSS I ON
This is the first systematic review assessing the risk of sex hormonedependent tumours in transgender individuals receiving genderaffirming hormone therapy, and it demonstrates a lack of data. As high-level evidence is not feasible, most of the evidence arises from retrospective cohort studies which, whilst the best evidence-todate, describe cohorts which are relatively young and have received on average insufficient durations of hormone therapy to meaningfully interpret the risk of tumour development.
| Retrospective Cohort Studies
Cohort studies summarized in Table 1 reveal that the most common cancer subtypes identified are not cancers commonly known to be hormone-dependent, unlike those featured in the case reports identified in this review. This likely reflects the fact that the absolute risk of common cancers still outweighs the smaller risk of cancers that may be more specific to those on exogenous hormone therapy.
Indeed, the all-cause cancer mortality data seem to be relatively closely aligned with population statistics in terms of which malignancies are most likely to cause death.
20
Whilst undoubtedly the best evidence available to date, the ability to derive meaningful conclusions from the cohort studies is affected by a number of inherent factors. Firstly, a small number of cancer cases were identified per study (rarely numbering > 10), which inevitably leads to large confidence intervals and suggests insufficient person-years to analyse these outcomes.
Secondly, mean time on GAHT is typically relatively short. In the largest US cohort of 2645 transgender individuals assessing breast cancer standardized incidence, mean time on hormonal therapy was only 7.6 years.
14 Multiple large-scale epidemiological studies have found that breast cancer risk increases with increasing duration of hormone replacement therapy in postmenopausal women and is highest after 5 or more years of exposure. 21 Compounding the insufficient duration of hormone therapy exposure, the mean age of the cohorts is typically young. As breast cancer has a median age of diagnosis of 61, even in the study with the longest hormone exposure of mean 21 years, this is insufficient to evaluate breast cancer risk in individuals who commenced therapy at mean age of 29.
13
Thirdly, retrospective cohort studies lack a true control population. As a result, confounding variables known to be important for cancer incidence are either not addressed or only controlled via post hoc statistical methods, rather than robust study design. In the largest cohort study assessing all-cause mortality in transgender individuals, lung cancer accounted for nearly 50% of the cancerrelated deaths. While smoking status was taken into account as a covariate in the calculation of statistical significance, it is unclear as to whether smoking pack-year history was considered and thus the extent to which this result is a product of longer smoking history in this population. 15 In studies evaluating breast cancer, important confounding factors relevant to female-to-male participants such as menarche, menopause status or parity are not addressed. 13, 14 Overall, at present, there are insufficient data to support a significant difference in cancer risk between transgender individuals on GAHT and the general population.
| Cross-sectional studies
Two cross-sectional surveys from the Ghent gender clinic have demonstrated mixed results. 18, 19 An initial survey of 100 individuals did not identify any cancer diagnoses; however, a later cross-sectional comparison of over 300 transgender individuals with an age-and gender-matched control population revealed rates of cancer similar to the general population. Rates of cancer diagnoses may appear reassuring; however, notably these were relatively young cohorts and longitudinal studies of greater duration are needed.
| Case reports
The internal validity and generalizability of case reports are inherently limited (summarized in Table 2 ). Inevitably, publication bias exists, as the types of cancers that have been reported are those that either are known to be sex hormone-dependent, to express sex hormone receptors or to have different prevalence rates amongst males and females. Despite this, published cases highlight some important hypotheses regarding how hormone therapy may affect certain malignancies.
| Case reports of tumours in male-to-female individuals
Breast cancer
Multiple studies have demonstrated that oestrogen and progesterone can stimulate breast cancer growth in females mediated via oestrogen receptors (ER) and progesterone receptors (PR). 22 Less is known about the role of sex hormones in the pathogenesis of breast cancer in birth-assigned males, although it has been observed that conditions that can cause high oestrogen levels (eg, obesity) have been associated with increased breast cancer in this population. 13 Several cases of male-to-female individuals diagnosed with breast cancer have been reported. As in the general female population, the overwhelming majority were invasive ductal carcinomas. 23 However, the cases are not homogenous in terms of their ER/PR expression, and thus, it is unclear as to the role of sex hormones in its pathogenesis.
Prostate cancer
Prostate cancer is exquisitely responsive to androgens and androgen deprivation has been used therapeutically for many decades. 24 Consistent with exogenous oestrogen or progesterone therapy, all cases reported of male-to-female individuals with prostate cancer have serum testosterone in the castrate range.
Whether exogenous oestrogen therapy had any direct role in tumour growth is unclear. Oestrogen does not seem to have a procarcinogenic effect on pre-existing prostate cancer, despite being associated with down-regulation of the antiproliferative β isoform of ER. 25 Furthermore, a review of 18 prospective studies found no association between the level of endogenous oestradiol and prostate cancer risk.
26
In the general population, prostate cancer that progresses despite medical castration, termed castration-resistant prostate cancer, signifies advanced disease with worse prognosis. 24 
Meningioma
High-dose cyproterone acetate is also a feature of the majority of meningioma case reports in male-to-female individuals. An association between high-dose cyproterone (defined as >50 mg/day) and meningioma risk in the general population has been observed. 27 In the published case reports, ER and PR status varies and the mechanism by which cyproterone acetate may contribute to meningioma development is unclear. Notably, most meningiomas in the general population express PR (with more variable expression of ER) 28 and the progestogenic effect of cyproterone may well play a role.
Prolactinoma
Both exogenous oestrogen and cyproterone acetate have been separately associated with increased serum prolactin levels in prospective cohort studies of transgender populations and oestradiol has been postulated to stimulate prolactin release. 29, 30 In fact, it may be the progestogenic effect of cyproterone acetate, not oestrogen, that is most important. 31 In a retrospective cohort study of 38 male-tofemale individuals, Nota and colleagues note that prolactin levels rose with the commencement of oestradiol and cyproterone acetate, but normalized to baseline levels following gonadectomy and cessation of cyproterone acetate. This was despite an unchanged postoperative oestradiol dose. 29 There are no large studies linking cyproterone acetate to frank prolactinoma development. Interestingly however, approximately half of the male-to-female individuals who developed prolactinomas in published case reports were on relatively high doses of cyproterone of at least 100 mg/day. [32] [33] [34] There are no case reports identifying prolactinomas in individuals on an alternative form of anti-androgen such as spironolactone. However, the role of oestrogen is still unknown given that multiple cases of prolactinomas have been identified in transgender individuals on exogenous oestrogen without any form of anti-androgen therapy.
35,36
| Case reports of neoplasms in female-to-male participants
The number of case reports published about hormone-dependent neoplasm diagnoses in the female-to-male population is smaller than that of male-to-female and the majority focus on breast cancer.
13,37-40
Breast cancer
As in the general female population, the majority of breast cancers identified were ER-positive (Table 2 ). Seven out of these eight case reports describe individuals who are below the mean age for breast cancer diagnosis. 20 As in the case of prostate cancer in male-tofemale individuals, it is unclear as to whether this reflects an inherent risk of testosterone therapy, whether testosterone has in some way selected for younger onset cases, or whether these individuals had a genetic predisposition to the development of breast cancer unrelated to hormone therapy. There is conflicting data in the literature as to whether testosterone is stimulatory towards breast cancer.
Higher endogenous testosterone levels are associated with an increased risk of breast cancer in premenopausal women. 41 Moreover, 
| Summary
Many tumour subtypes express sex hormone receptors, and the potential impact of long-term GAHT requires further study. Oestrogen with or without anti-androgen therapy may be associated with prolactinomas and high-dose cyproterone acetate may be associated with increased meningioma risk, but there is currently insufficient evidence to support screening. Using the lowest effective dose of oestradiol and cyproterone acetate to achieve feminization and suppress testosterone levels, respectively, is a reasonable approach.
Further research is needed to clarify the effect of GAHT on tumour development, particularly consideration for longitudinal follow-up of cohorts over time. Incorporation of gender options other than male and female in existing health databases is needed to accurately identify transgender individuals and allow meaningful inferences from large epidemiological data sets.
14 Whilst considering potential long-term tumour risk, it should be noted that the benefits of gender-affirming hormonal therapy on mortality from suicide prevention and improved quality of life far outweigh any potential risk. 12, 15, 16 Thus, while more research in this area is needed to clarify the long-term risks of hormone therapy, clinical decisions are made on an informed, balanced risk-to-benefit consideration between treating clinicians and individuals.
| CON CLUS IONS
Although theoretically plausible, there are no well-designed studies of sufficient duration to suggest GAHT increases the risk of hormone-dependent tumour development. Until more conclusive evidence is available, the minimum dose of hormone therapy to achieve masculinization or feminization is a sensible approach. 
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